Key Takeaways
- Breye Therapeutics raised $73.3M (Series A) from Mission BioCapital, Novo Holdings, Sound Bioventures.
- Sector: Biotechnology & Life Sciences, Healthcare, Healthtech & Medtech.
- Geography: Denmark.
Analysis
- Breye Therapeutics has successfully closed an oversubscribed Series A financing round.
- The company is focused on developing oral therapies for early-stage retinal diseases.
- The funding round was co-led by Mission BioCapital and Novo Holdings.
- Existing investor Sound Bioventures also participated in the round.
- The capital raised will be used to advance the development of their oral therapies.